Wolfe Research Upgrades Immunovant to Outperform, Announces $50 Price Target
Benzinga Newsdesk 10 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperform and announces $50 price target.
Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperform and announces $50 price target.